V. S. Shcherbakova

ORCID: 0000-0002-7251-8744
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer therapeutics and mechanisms
  • Synthesis and Characterization of Heterocyclic Compounds
  • Circadian rhythm and melatonin
  • Human Health and Disease
  • Phenothiazines and Benzothiazines Synthesis and Activities
  • Diet, Metabolism, and Disease
  • Spaceflight effects on biology
  • Pharmacological Effects of Natural Compounds
  • Drug-Induced Hepatotoxicity and Protection
  • Synthesis and biological activity
  • Mycobacterium research and diagnosis
  • Colorectal Cancer Treatments and Studies
  • COVID-19 Clinical Research Studies
  • Tuberculosis Research and Epidemiology
  • SARS-CoV-2 and COVID-19 Research
  • Infectious Encephalopathies and Encephalitis
  • Sympathectomy and Hyperhidrosis Treatments
  • Wound Healing and Treatments
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Immunotoxicology and immune responses
  • Anesthesia and Sedative Agents
  • Carcinogens and Genotoxicity Assessment
  • Biochemical and Molecular Research
  • Periodontal Regeneration and Treatments
  • Amino Acid Enzymes and Metabolism

Ministry of Health of the Russian Federation
2020

Tuberculosis is a chronic infectious disease, usually localized in the respiratory system and representing one of most important global social biomedical health problems associated with spread therapy-resistant forms (multidrug-resistant extensively drug-resistant tuberculosis). One promising targets for development antimycobacterial drugs enzyme DprE1, which involved synthesis cell wall mycobacteria. In series DprE1 inhibitor drugs, advanced drug PBTZ169 (INN maсozinone). Clinical trials...

10.26442/00403660.2020.03.000621 article EN cc-by-nc Terapevticheskii arkhiv 2020-03-27

Macozinone (MCZ; PBTZ169) is a first-in-class antituberculosis clinical-stage benzothiazinone-based drug candidate. Although its efficacy and safety have been strongly proven in several preclinical clinical studies, the physicochemical pharmacokinetic properties specific to MCZ required further optimization. Accordingly, this study aimed evaluate pharmacokinetics of administered as extended-release (ER) tablets F2 F6 compared immediate-release (IR) dispersible for oral suspension. Oral...

10.1128/spectrum.02327-22 article EN cc-by Microbiology Spectrum 2022-12-12

Active collagen type I successfully used in regenerative medicine. However, despite the large amount of material cellular and molecular mechanisms underlying skin repair, wound healing with use I, not studied enough.To study mechanism native wound-healing action on example medical device Collost (7% gel) a model rats difficult-to-heal wounds.Male population SD (72 individuals) surgically formed an ischemic dorsal flap (3×10 cm) two full-thickness wounds 6 mm diameter.The trained animals...

10.17116/hirurgia202010179 article RU Pirogov Russian Journal of Surgery 2020-01-01

Tuberculosis (TB) is one of the top ten causes death worldwide. Improvement treatment options via development new drugs and regimens that would be more convenient for patients key improving effecacy TB prevention careis. Since creation by minimizing number used reducing duration most promising correct direction, macozinone, a candidate benzothiazinone series, can become basis chemotherapy drug-resistant forms including combination macozinone with effective modern anti-TB drugs. Comparative...

10.26442/00403660.2020.12.200482 article EN cc-by-nc Terapevticheskii arkhiv 2020-12-15

Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). The new drug Areplivir® Zinc as a combination of favipiravir (200 mg) zinc gluconate (70 in form film-coated tablets has been developed by LLC "PROMOMED RUS", Russia. This could provide more effective treatment COVID-19. Aim. aim pharmacokinetics study comparison between (INN: +...

10.33380/2305-2066-2024-13-1-1764 article EN cc-by Drug development & registration 2024-02-27

Introduction. COVID-19 (Coronavirus disease 2019) almost 4 years after he start of the pandemic is still a significant public health problem. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) that causes continues to mutate and spread throughout world. Molnupiravir favipiravir have been shown be efficacious against variety RNA viruses including SARS-CoV-2. The Ministry Health Russian Federation approved use these drugs as treatment COVID-19. developed drug contains combination two...

10.33380/2305-2066-2024-13-1-1761 article EN cc-by Drug development & registration 2024-02-27

Introduction. The introduction of devices – analogues GIS (hereinafter–- Gastro-intestinal simulator) is one the current ways to develop in-vitro assessment quality solid dosage forms. Testing on a physiologically relevant test device (hereinafter referred as PRT) makes it possible predict pharmacokinetic profiles due more conditions, including use biorelevant dissolution media, physiological volumes gastrointestinal tract, well transit between them. Aim. Conduct study cladribine tablets...

10.33380/2305-2066-2024-13-3-1890 article EN cc-by Drug development & registration 2024-08-15

10.1007/bf00835913 article EN Bulletin of Experimental Biology and Medicine 1986-03-01
Coming Soon ...